RecallRadar

FDA Drug recall D-0390-2021

Cefixime for Oral Suspension USP 100 mg/5mL, 50mL HDPE bottles, Rx Only, Manufactured by: Lupin Pharmaceuticals, Inc

On 2021-05-26 the FDA classified a Class II recall of Cefixime for Oral Suspension USP 100 mg/5mL, 50mL HDPE bottles, Rx Only, Manufactured by: Lupin Pharmaceuticals, Inc by Lupin Pharmaceuticals, citing subpotent Drug.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0390-2021
ClassificationClass II
Statusterminated
Initiated2021-04-29
Published2021-05-26
Last updated2026-09-13 11:52 UTC
CompanyLupin Pharmaceuticals
DistributionUS

Product

Cefixime for Oral Suspension USP 100 mg/5mL, 50mL HDPE bottles, Rx Only, Manufactured by: Lupin Pharmaceuticals, Inc. Baltimore, Maryland, 21202 United States, Manufactured by: Lupin Limited, Manddeep, 462 046, India, NDC 68180-405-01

Reason

Subpotent Drug

Identifiers

ndc68180-405-01
ndc68180-407-03
ndc68180-407-04
ndc68180-416-08
ndc68180-416-11
ndc68180-423-11
ndc68180-423-08
code_infoLot #: F900787, Exp. Date 4/2021

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0390-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.